| 000 | 01895 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514015121.0 | ||
| 264 | 0 | _c20011231 | |
| 008 | 200112s 0 0 eng d | ||
| 022 | _a0014-5793 | ||
| 024 | 7 |
_a10.1016/s0014-5793(01)02990-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCulbert, A A | |
| 245 | 0 | 0 |
_aGSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. _h[electronic resource] |
| 260 |
_bFEBS letters _cNov 2001 |
||
| 300 |
_a288-94 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdaptor Proteins, Signal Transducing |
| 650 | 0 | 4 |
_aAdenoviridae _xgenetics |
| 650 | 0 | 4 |
_aAminophenols _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCalcium-Calmodulin-Dependent Protein Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCarrier Proteins |
| 650 | 0 | 4 |
_aCytoplasm _xmetabolism |
| 650 | 0 | 4 |
_aCytoskeletal Proteins _xmetabolism |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aGene Expression Regulation |
| 650 | 0 | 4 | _aGlycogen Synthase Kinase 3 |
| 650 | 0 | 4 | _aGlycogen Synthase Kinases |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 |
_aMaleimides _xpharmacology |
| 650 | 0 | 4 | _aNeoplasm Proteins |
| 650 | 0 | 4 |
_aNeurons _xdrug effects |
| 650 | 0 | 4 | _aNeuroprotective Agents |
| 650 | 0 | 4 | _aPC12 Cells |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins _xgenetics |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aTrans-Activators |
| 650 | 0 | 4 | _abeta Catenin |
| 650 | 0 | 4 |
_atau Proteins _xmetabolism |
| 700 | 1 | _aBrown, M J | |
| 700 | 1 | _aFrame, S | |
| 700 | 1 | _aHagen, T | |
| 700 | 1 | _aCross, D A | |
| 700 | 1 | _aBax, B | |
| 700 | 1 | _aReith, A D | |
| 773 | 0 |
_tFEBS letters _gvol. 507 _gno. 3 _gp. 288-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0014-5793(01)02990-8 _zAvailable from publisher's website |
| 999 |
_c11611862 _d11611862 |
||